Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI (RVuptakeLexi)

November 3, 2015 updated by: Aiden Abidov

Diagnostic and Prognostic Value of the Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI in Patients With Known or Suspected Coronary Artery Disease (CAD).

The objectives of this study are to determine the:

  1. Diagnostic value of stress induced RV changes on Lexiscan stress MPI as compared to Exercise stress MPI in predicting a significant CAD.
  2. Prognostic value of stress induced RV changes on Lexiscan stress MPI in predicting adverse short-term and long-term clinical outcomes after the index test.

Study Overview

Detailed Description

Phase 1: Retrospective data collection/analysis All Lexiscan and exercise MPI images on patients performed for clinical indications in calendar year 2010 who had subsequent coronary angiogram within 3 months after index MPI will be retrieved for review by two experts. We will identify different types of RV uptake and RV overload during stress as well as presence or absence of these changes on resting images. Analysis will include increased RV uptake, enlargement, hypertrophy, thinning of RV and flattening of the interventricular septum. Diagnostic performance (sensitivity, specificity and diagnostic accuracy) of the identified pathological RV phenotypes in identifying severe and extensive disease will be evaluated by comparison with contrary angiograms. Comparison of the set of parameters identifying pathological RV changes, identifying normal and abnormal values of these novel ancillary markers, as well as assessing their diagnostic accuracy in patients with suspected and known CAD during vasodilator stress versus exercise stress MPI will be done.

Phase 2: Prospective data validation Patients referred for the Lexiscan stress MPI will be followed prospectively after obtaining an informed consent. All comers after June 1 2012 will be included. Prediction of coronary artery disease will be performed by applying the previously derived pathological RV criteria on the prospective stress MPIs. 2D-Echocardiogram will be performed for all the patients who do not have an Echocardiogram performed for clinical indication within 1 month of their index Lexiscan stress MPI. We will also include 100 patients referred for the exercise stress MPI who will serve as controls.

All patients will be prospectively followed up for a total of 12 months for the following prognostic end points:

  1. Hard cardiac events (cardiac death or MI);
  2. Total (all-cause) mortality;
  3. Cardiovascular hospitalization rate. Cardiac death (CD) will be defined as death attributable to any cardiac cause (eg, lethal arrhythmia, myocardial infarction [MI], or pump failure) as confirmed by review of death certificate and medical records.

Study Type

Observational

Enrollment (Anticipated)

650

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arizona
      • Tucson, Arizona, United States, 85724
        • University of Arizona Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 89 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. Retrospective population (approximately 300 charts to be reviewed)

    • Patients with MPI and 2D Echocardiogram within one month of the stress testing in calendar year 2010 at University Medical Center, Tucson AZ.
    • 18 years or older
  2. Prospective population (approximately 350 subjects to be recruited)

    • Patients scheduled for MPI at University Medical Center, Tucson AZ, and invited to participate in this study.
    • 18 years to 89 years old

Description

Inclusion Criteria:

  1. Retrospective population (approximately 300 charts to be reviewed)

    • Patients with MPI and 2D Echocardiogram within one month of the stress testing in calendar year 2010 at University Medical Center, Tucson AZ.
    • 18 years or older.
  2. Prospective population (approximately 350 subjects to be recruited)

    • Patients scheduled for MPI at University Medical Center, Tucson AZ.
    • 18 years to 89 years old

Exclusion Criteria (applied to both retrospective and prospective arms):

  • patients with nondiagnostic or technically defective MPI
  • incomplete clinical data
  • severe valvular heart disease
  • complex congenital heart disease
  • life expectancy less than one year at the time of the index MPI
  • unable to follow up (absence of permanent address)
  • Known prisoners, pregnant women and cognitively impaired patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control

Cohorts and Interventions

Group / Cohort
Lexiscan-Echo echo subjects
No Intervention: Observational study
Lexiscan-Echo control subjects
No intervention: observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hard cardiac events (cardiac death or MI)
Time Frame: within 1 year after the index test
Patient follow-up evaluated for hard cardiac events (cardiac death or MI)in the year post index test determined by telephone interviews or review of medical records
within 1 year after the index test

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total (all-cause) mortality
Time Frame: within 1 year after the index test
Total (all-cause) mortality in the year post index test determined by telephone interviews or review of medical records
within 1 year after the index test
Cardiovascular hospitalization rate
Time Frame: within 1 year after the index test
Cardiovascular hospitalization rate in the year post index test determined by telephone interviews or review of medical records
within 1 year after the index test

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Aiden Abidov, MD, University of Arizona

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Anticipated)

June 1, 2016

Study Completion (Anticipated)

December 1, 2016

Study Registration Dates

First Submitted

August 6, 2012

First Submitted That Met QC Criteria

September 27, 2012

First Posted (Estimate)

October 2, 2012

Study Record Updates

Last Update Posted (Estimate)

November 4, 2015

Last Update Submitted That Met QC Criteria

November 3, 2015

Last Verified

November 1, 2015

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Increased Right Ventricular Radiotracer Uptake

3
Subscribe